However, downregulated expression of CXXC5 is associated with low-risk abnormalities and higher overall survival in patients with newly diagnosed AML receiving intensive chemotherapy, indicating that CXXC5 may act as a tumor suppressor involved in tumor development [47, 89, 93]. This evidence concerns the gene CXXC5 and acute myeloid leukemia.